Ritonavir is the most potent cytochrome P450 (CYP) 3A4 inhibitor in clinical use and is often
applied as a booster for drugs with low oral bioavailability due to CYP3A4-mediated …

CYP3A is an enzyme subfamily in the cytochrome P450 (CYP) superfamily and includes
isoforms CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A enzymes are indiscriminate …

The accurate prediction of pharmacokinetics (PK) is fundamental to underwriting safety and
efficacy in pediatric clinical trials; age‐dependent PK may be observed with pediatrics …

Drug–drug interactions (DDIs) occur commonly and may lead to severe adverse drug
reactions if not handled appropriately. Considerable information to support clinical decision …

Rationale: Various in vitro, animal, and limited human adult studies suggest a profound
inhibitory effect of inflammation and disease on cytochrome P-450 3A (CYP3A)-mediated …

The dissolution, intestinal absorption and presystemic metabolism of a drug depend on its
physicochemical characteristics but also on numerous physiological (eg gastrointestinal pH …

Drug metabolism importantly determines drug concentrations. The efficacy and safety of
many drugs prescribed for children are, therefore, dependent on intraindividual and …

Capturing ontogeny of enzymes involved in phase I metabolism is crucial to improve
prediction of dose‐concentration and concentration‐effect relationships throughout infancy …

Developmental and physiological changes in children contribute to variation in drug
disposition with age. Additionally, critically ill children suffer from various life-threatening …

Therapeutic hypothermia (TH) is standard treatment for neonates (≥ 36 weeks) with
perinatal asphyxia (PA) and hypoxic–ischemic encephalopathy. TH reduces mortality and …